

## **AGENDA**

***Uniform Formulary Beneficiary Advisory Panel  
24 March 2011 @ 0900 AM***

***Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004***

- **Administrative Meeting (BAP members only @ 7:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations of the following drug classes during the November 2010 meeting:*

- ***Drug Class Reviews:***
  - ***Gastrointestinal-1 (GI-1s) Drugs***
    - ***Aminosalicylates (ASAs)***
    - ***GI Topical Steroids***
    - ***Miscellaneous Agents (tegaserod, alosetron)***
  - ***Antilipidemic-2 (LIP-2s) Drugs***
    - ***Fibric Acids***
    - ***Prescription Omega-3 Fatty Acids***
    - ***Bile Acid Sequestrants***
  - ***Pancreatic Enzyme Products (PEPs)***
- ***Designated Newly Approved Drugs:***
  - ***Renin Angiotensin Antihypertensive Agents (RAAs)***
    - ***Tekamlo (aliskiren/amlodipine tablets)***
    - ***Tribenzor (olmesartan/amlodipine/hydrochlorothiazide tablets)***

- *Antiemetics—Zuplenz (ondansetron oral soluble film)*
- *Alzheimer’s Drugs—Aricept 23 mg (donepezil 23 mg tablets)*
- *Self Monitoring Blood Glucose Systems (SMBGS) test strips*
  - *Glucocard 01*
  - *Glucocard Vital*
  - *Nova Max*
  - *Embrace*
- *Utilization Management—Prior Authorization:*
  - *Qulaquin (quinine sulfate) prior authorization – recommendation for quantity limits*
- *Items for Information—Darvon/Darvocet (propoxyphene) withdrawal from the market*

➤ **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*